Our findings suggest that the balance of IRF4 partner expression between SPIB and BATF identifies distinct subgroups of ABC-DLBCL linked to different stages of B-cell differentiation, oncogenic pathway activation and clinical outcome. This evidence concerns the gene IRF4 and diffuse large B-cell lymphoma.